Concourse Financial Group Securities, Inc. Reviva Pharmaceuticals Holdings, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.67 Billion
Q4 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share
Q4 2024 Feb 13, 2025	BUY	$0.92 - $2.82 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$0.64 - $1.48 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$1.25 - $3.79 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$2.76 - $5.52 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$3.56 - $6.04 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$3.91 - $5.9 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$3.91 - $5.9 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$4.42 - $8.55 $0 - $0
Q1 2023 May 15, 2023	BUY	$3.79 - $4.87 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.68 - $5.99 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$0.14 - $2.66 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.03 - $2.47 $0 - $0
Q1 2022 May 09, 2022	BUY	$1.61 - $3.01 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$2.7 - $4.23 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$3.29 - $4.79 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$4.05 - $8.7 $0 - $0
Q1 2021 May 13, 2021	BUY	$5.4 - $9.49 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$7.92 - $11.16 $0 - $0

Others Institutions Holding RVPH

# of Institutions

Shares Held

7.83M

Call Options Held

628K

Put Options Held

338K

Israel Englander Millennium Management LLC | New York, Ny

1.8M
Shares

$3.25 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

1.38M
Shares

$2.49 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

1.36M
Shares

$2.46 Million
0.03% of portfolio
Schonfeld Strategic Advisors LLC New York, NY

1.06M
Shares

$1.9 Million
0.01% of portfolio
Parkman Healthcare Partners LLC Stamford, CT

514K
Shares

$925,691
0.13% of portfolio

View Full List

About REVIVA PHARMACEUTICALS HOLDINGS, INC.

Ticker RVPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,442,900
Market Cap $36.8M
Description
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP506...

More about RVPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account